U.S. Markets close in 17 mins
  • S&P 500

    4,514.03
    -63.07 (-1.38%)
     
  • Dow 30

    34,423.06
    -216.73 (-0.63%)
     
  • Nasdaq

    14,990.56
    -390.75 (-2.54%)
     
  • Russell 2000

    2,156.34
    -49.99 (-2.27%)
     
  • Crude Oil

    66.06
    -0.44 (-0.66%)
     
  • Gold

    1,785.40
    +22.70 (+1.29%)
     
  • Silver

    22.53
    +0.22 (+0.98%)
     
  • EUR/USD

    1.1310
    +0.0004 (+0.0339%)
     
  • 10-Yr Bond

    1.3430
    -0.1050 (-7.25%)
     
  • Vix

    31.49
    +3.54 (+12.67%)
     
  • GBP/USD

    1.3231
    -0.0071 (-0.5319%)
     
  • USD/JPY

    112.7500
    -0.4590 (-0.4054%)
     
  • BTC-USD

    52,871.92
    -4,323.42 (-7.56%)
     
  • CMC Crypto 200

    1,336.37
    -105.39 (-7.31%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

Biogen says ALS drug did not meet primary endpoint in Phase 3 clinical trial

·1 min read
Biogen says ALS drug did not meet primary endpoint in Phase 3 clinical trial
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Biogen were down 0.6% in premarket trading on Monday, the day after the company said an experimental amyotrophic lateral sclerosis (ALS) drug did not meet the primary endpoint in an open-label, Phase 3 clinical trial. Biogen said it is considering next steps for the investigational drug, tofersen, which was being tested in people with a rare form of the neurodegenerative disease. "These preliminary data may be supportive of some hints of efficacy; however, the study failed the well-und